Crispr Therapeutics AG (CRSPN)

Mexico
Currency in MXN
737.00
0.00(0.00%)
Closed·
CRSPN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week Low
Fair Value
Day's Range
737.00737.00
52 wk Range
737.001,190.00
Key Statistics
Edit
Bid/Ask
737.00 / 900.00
Prev. Close
737
Open
737
Day's Range
737-737
52 wk Range
737-1,190
Volume
150
Average Volume (3m)
108
1-Year Change
-23.23%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRSPN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Crispr Therapeutics AG Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Employees
393
Market
Mexico

Compare CRSPN to Peers and Sector

Metrics to compare
CRSPN
Peers
Sector
Relationship
P/E Ratio
−8.9x−0.6x−0.5x
PEG Ratio
0.070.000.00
Price/Book
1.7x1.0x2.6x
Price / LTM Sales
86.9x9.1x2.9x
Upside (Analyst Target)
-519.8%64.0%
Fair Value Upside
Unlock23.6%9.4%Unlock

Earnings

Latest Release
Feb 11, 2025
EPS / Forecast
-0.44 / --
Revenue / Forecast
35.69M / --
EPS Revisions
Last 90 days

People Also Watch

43.23
TEM
+5.49%
100.55
ARM
+3.84%
42.09
HOOD
+5.62%
10.47
PATH
+2.55%

FAQ

What Is the Crispr Therapeutics (CRSPN) Stock Price Today?

The Crispr Therapeutics stock price today is 737.00

What Stock Exchange Does Crispr Therapeutics Trade On?

Crispr Therapeutics is listed and trades on the Mexico stock exchange.

What Is the Stock Symbol for Crispr Therapeutics?

The stock symbol for Crispr Therapeutics is "CRSPN."

What Is the Crispr Therapeutics Market Cap?

As of today, Crispr Therapeutics market cap is 66.11B.

What is Crispr Therapeutics Earnings Per Share?

The Crispr Therapeutics EPS is -4.34.

From a Technical Analysis Perspective, Is CRSPN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.